Status:
UNKNOWN
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
Lead Sponsor:
Affiliated Hospital of Nantong University
Collaborating Sponsors:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions:
Non-alcoholic Fatty Liver Disease
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD). INTERVENTION PROGRAM: All subjects underwent di...
Detailed Description
1. Randomization Patients were divided into three groups by lifestyle intervention + orlistat treatment, in lifestyle intervention + liraglutide treatment and in lifestyle intervention + orlistat + li...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Metabolic Associated Fatty Liver Disease(MAFLD);
- Clinical diagnosis of Obesity.
Exclusion
- Medicated Hepatitis and Viral Hepatitis;
- Have severe hepatic or renal insufficiency;
- have used any weight-loss drug;
- History of severe gastrointestinal disorders;
- Malignant tumors, autoimmune diseases, hematologic diseases;
- Psychopath;
- Women who are pregnant, breastfeeding or preparing for pregnancy;
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2025
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06501326
Start Date
November 1 2023
End Date
February 28 2025
Last Update
July 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China